Virta Health Highlights Lasting, Transformative Health Improvements In 5-Year Diabetes Reversal Study
The Californer/10195075

Trending...
Download
The outcomes of Jane Ann and Virta's other trial patients contradict the belief that progression of diabetes—and a lifetime of increasing medications—is inevitable. (Photo: Business Wire)
SAN FRANCISCO--(BUSINESS WIRE)--Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions. Presenting four unique abstracts, Virta highlighted myriad, lasting health improvements for people with type 2 diabetes and prediabetes, including blood sugar control, clinically-significant weight loss, reduced inflammation, and improvements in other markers of cardiometabolic health.

These transformative health outcomes coincided with medication reduction or elimination for many trial patients, including Jane Ann Dimitt.

For over two decades, Jane Ann was prescribed increasing levels of medications as her blood sugar and weight continued to climb. By the time she joined Virta in 2015, her A1c had reached 11.4%; the next step was insulin. Through Virta's treatment, Jane Ann lowered her blood sugar to 5.5% (below even the prediabetes threshold) and lost over 50 pounds, while drastically reducing her reliance on medications. She also saw improved mobility, decreased inflammation and neuropathy, and now has the energy to play with her grandchildren—all without needing the insulin doctors said was imminent.

The outcomes of Jane Ann and Virta's other trial patients contradict the belief that progression of diabetes—and a lifetime of increasing medications—is inevitable. One-fifth of Virta patients completing five years of treatment saw full remission (A1c <6.5% without any diabetes medications for at least 3 months). One-third of patients achieved A1c below 6.5% without any diabetes medications, or only requiring Metformin. Notably, inflammatory markers, triglycerides, and HDL cholesterol all improved significantly.

More on The Californer
These outcomes, in conjunction with previous research demonstrating improvements in cardiovascular disease risk factors, depression symptoms, sleep, and knee pain, establish the promise of Virta's approach to impact a wide range of conditions amid America's metabolic disease epidemic. In the U.S., costs are rising as patient outcomes continue to worsen, including surges in amputations, hyperglycemic events (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.reuters.com%2Finvestigates%2Fspecial-report%2Fusa-diabetes-covid%2F&esheet=52739937&newsitemid=20220605005111&lan=en-US&anchor=amputations%2C+hyperglycemic+events&index=8&md5=2e3320116278922759106e982ad2af81), and diabetes-related deaths (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.reuters.com%2Fworld%2Fus%2Fexclusive-us-diabetes-deaths-top-100000-second-straight-year-federal-panel-urges-2022-01-31%2F&esheet=52739937&newsitemid=20220605005111&lan=en-US&anchor=diabetes-related+deaths&index=9&md5=e39ed119a40d3ce7e9e36ac0987510e9) during the COVID-19 pandemic.

Meanwhile, getting patients to stick with an intervention remains a significant challenge in diabetes therapy. Rates of medication adherence—that is, whether patients take their medications as prescribed—fall as low as 34% (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5984924%2Fpdf%2F13300_2018_Article_421.pdf&esheet=52739937&newsitemid=20220605005111&lan=en-US&anchor=as+low+as+34%25&index=10&md5=00e21edc56c3f66c7471d8775aff38cb) over the first three years for those starting insulin. For the National Diabetes Prevention Program, considered the gold standard in lifestyle interventions, only 13% (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5606310%2F&esheet=52739937&newsitemid=20220605005111&lan=en-US&anchor=only+13%25&index=11&md5=c9a1c55e9ea7fb36a0654e0fffc78796) of patients were retained at one year.

More on The Californer
In contrast, in Virta's trial nearly 50% of participants with type 2 diabetes were retained at five years. Of those who continued past year two, 72% remained for an additional three years to year five. For Kim Shepherd, who lost 55 pounds, eliminated 10 different medications, reversed her diabetes, and even saw her GERD (acid reflux) and plantar fasciitis disappear, the reasons to stick with the treatment are clear.

"Diabetes runs in my family, and I know that this disease can rob you of your whole life; it can take your eyes, your feet, and your kidneys. I have 4 kids and 9 grandkids to keep up with. I've learned to love hiking and biking. Nothing is worth losing all of that and going back to how I was before."

Additional key outcomes demonstrating the success of Virta's approach at five years include:
  • Sustained blood sugar control. Virta patients experienced persistent improvements in blood sugar on average, while requiring significantly fewer medications.
  • Medication deprescription. Half of patients prescribed insulin at the start of the trial no longer needed it at five years. Across all diabetes drugs, prescriptions were reduced by nearly 50%.
  • Weight loss. Average weight among Virta participants decreased by 7.6%, exceeding the 5% benchmark for clinically significant weight loss by more than 50%.
  • Broad improvement in cardiometabolic health. In addition to improvements in triglycerides, HDL cholesterol, and markers of inflammation, patients even showed encouraging signs in reversing the progression of chronic kidney disease.

"Virta's patients are helping redefine what long-term success can look like in type 2 diabetes care," said Dr. Alan Moses, former Senior Vice President and Global Chief Medical Officer of Novo Nordisk, and Virta advisor. "The patient outcomes set a new standard for real-world applications of diabetes treatment."

Trial participants with prediabetes also saw meaningful improvements, with progression rates far below what has been demonstrated in other studies. Further, Virta patients sustained 6% weight loss over five years, exceeding the clinically-significant benchmark for diabetes prevention and far surpassing the 2% weight loss observed in the NIH (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3135022%2F&esheet=52739937&newsitemid=20220605005111&lan=en-US&anchor=NIH&index=12&md5=0a67067cf6686166b60e7829e6868356) Diabetes Prevention Program lifestyle intervention (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3135022%2F&esheet=52739937&newsitemid=20220605005111&lan=en-US&anchor=Diabetes+Prevention+Program+lifestyle+intervention&index=13&md5=f58a0f8f9e9ea3c553567454083d6e37).

The study is also notable for its longevity. Five-year published results are extremely rare in digital health, where most studies follow populations for no more than a year, and usually significantly less. For many Virta patients, the five-year clinical trial has facilitated a lasting lifestyle change, improving not only traditional markers of health but overall mood, quality of life, and outlook on the future.

Says patient Denise Lamb, who has maintained diabetes reversal alongside a nearly 70 pound weight loss, "My journey has been phenomenal. The Virta program has not only helped me achieve healthy blood glucose, but also attain a far better weight, normal blood pressure, and better understanding of my body. Virta's lifestyle changed my lifestyle!"

About Virta Health:

Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches manage disease progression through increased medication use and infrequent doctor visits. Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. In clinical studies, 94% of patients reduce or eliminate insulin use, and weight-loss exceeds FDA benchmarks by nearly 150%. Virta works with the largest health plans, employers, and government organizations and puts 100% of its fees at risk based on clinical and financial outcomes. To learn more about how Virta is transforming lives by reversing type 2 diabetes and other chronic diseases, visit www.virtahealth.com (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.virtahealth.com&esheet=52739937&newsitemid=20220605005111&lan=en-US&anchor=www.virtahealth.com&index=14&md5=a613e94a67da4d8c760674889f627f40) or follow us on Twitter @virtahealth (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2Fvirtahealth&esheet=52739937&newsitemid=20220605005111&lan=en-US&anchor=%40virtahealth&index=15&md5=30e0627a24d169ff92c0a82226cb8125).

Contacts

Media Contact:
Lauren Cunningham
lauren.volkmann@virtahealth.com
831-331-3307

0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>

Social Media Profiles
  • Virta Health on Facebook (https://www.facebook.com/virtahealth/)
  • Virta Health on Twitter (https://twitter.com/virtahealth)
  • Virta Health on LinkedIn (https://www.linkedin.com/company/virta-health)

Contacts

Media Contact:
Lauren Cunningham
lauren.volkmann@virtahealth.com
831-331-3307
Filed Under: Business
Show All News | Disclaimer | Report Violation

0 Comments

Latest on The Californer